ProQR Therapeutics N.V. (PRQR)
PRQRNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$1.40
+0.0500 (+3.70%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $194.75m
- P/E
- –
- EPS, last 4 quarters
- $-0.4600
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.20 to $2.49
- Average volume
- 767.9k
- Previous close
- $1.35
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $8.25, +489.3% from here
Earnings
next estimate $-0.1100Next report
Sep 2025
-20.0%
Dec 2025
-12.5%
Mar 2026
0.0%
Jun 2026
+28.6%
estimate reported, and the surprise
Financials
No quarterly figures from the source.
News
8 latest- ProQR Therapeutics N.V. to Present Clinical and Preclinical Progress from AX-0810 and AX-0811 at Upcoming ConferencesFintel · Oct 28, 2026
- ProQR Reports First Human Validation of RNA Editing Platform in Liver DiseaseMarketBeat · Oct 2, 2026
- ProQR Establishes First Clinical Validation Of Axiomer Platform; AX-0811 Data Due By Year-End RTTNews · Aug 20, 2026
- Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue EstimatesZacks · Aug 14, 2026
- ProQR Prices Direct Offering And Private Placement For $59 Mln In Gross Proceeds; Stock Falls 20% RTTNews · Jun 26, 2026
- ProQR Therapeutics Announces Positive Target Engagement Data From Ongoing Phase 1 AX-0810 Study RTTNews · Jun 25, 2026
- Kamada (KMDA) Misses Q1 Earnings and Revenue EstimatesZacks · May 13, 2026
- Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to DeclineZacks · May 7, 2026
The company
ProQR Therapeutics is a clinical-stage company dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer, which uses a cell's own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- Europe
- Website
- proqr.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.